Advanced search
Publication Cover
Infection and Drug Resistance Volume 16, 2023 - Issue
Submit an article Journal homepage
119
Views
1
CrossRef citations to date
0
Altmetric
CASE REPORT

Diagnosis and Management of Drug-Induced Interstitial Lung Disease Associated with Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium Avium Complex Pulmonary Disease: A Case Report

Kazuki HashimotoDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, JapanView further author information
,
Takuro NiiDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, JapanCorrespondence[email protected]
View further author information
,
Hitoshi SumitaniDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, JapanView further author information
,
Masashi YokoyamaDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, JapanView further author information
,
Satoshi MiyamotoDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, JapanView further author information
,
Yasuhiro MihashiDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, JapanView further author information
,
Yuka NagataDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, JapanView further author information
,
Takanori MatsukiDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, JapanView further author information
,
Kazuyuki TsujinoDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, JapanView further author information
,
Keisuke MikiDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, JapanORCID Iconhttps://orcid.org/0000-0002-3600-8595View further author information
ORCID Icon &
Hiroshi KidaDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, JapanORCID Iconhttps://orcid.org/0000-0002-9351-7855View further author information
ORCID Icon show all
Pages 6629-6634 | Received 26 Jun 2023, Accepted 27 Sep 2023, Published online: 10 Oct 2023

References

  • Fukushima K, Kitada S, Abe Y, et al. Long-term treatment outcome of progressive Mycobacterium avium complex pulmonary disease. J Clin Med. 2020;9(5):1315. doi:10.3390/jcm9051315
  • Fukushima K, Kida H. New/different look at the presence of Aspergillus in mycobacterial pulmonary diseases. Long-term retrospective cohort study. Microorganisms. 2021;9(2):270. doi:10.3390/microorganisms9020270
  • Lee SH, Lee JH, Chang JH, et al. Hemoptysis requiring bronchial artery embolization in patients with nontuberculous mycobacterial lung disease. BMC Pulm Med. 2019;19(1):117. doi:10.1186/s12890-019-0881-z
  • Yamamoto Y, Tsujino K, Kuge T, et al. Pleuroparenchymal fibroelastosis in Mycobacterium avium complex pulmonary disease: clinical characteristics and prognostic impact. ERJ Open Res. 2021;7(1):00765–2020. doi:10.1183/23120541.00765-2020
  • Terzano C, Petroianni A. Clarithromycin and pulmonary infiltration with eosinophilia. BMJ. 2003;326(7403):1377–1378. doi:10.1136/bmj.326.7403.1377
  • Saha K, Bandyopadhyay A, Sengupta A, Jash D. A rare case of ethambutol induced pulmonary eosinophilia. J Pharmacol Pharmacother. 2013;4(4):300–302. doi:10.4103/0976-500X.119724
  • Nishio C, Sato A, Tsuboi T, Sumi K, Kurasawa T. Pneumonitis induced by rifampicin. Kekkaku. 2011;86(4):473–476.
  • Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012;13(1):39. doi:10.1186/1465-9921-13-39
  • Griffith DE, Eagle G, Thomson R, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium Complex (CONVERT). A prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018;198(12):1559–1569. doi:10.1164/rccm.201807-1318OC
  • Winthrop KL, Flume PA, Thomson R, et al. Amikacin liposome inhalation suspension for Mycobacterium avium complex lung disease: a 12-month open-label extension clinical trial. Ann Am Thorac Soc. 2021;18(7):1147–1157. doi:10.1513/AnnalsATS.202008-925OC
  • Kidogawa M, Yamasaki K, Nemoto K, Yatera K. Liposomal amikacin inhalation suspension-induced pneumonitis. Intern Med. 2022;61(16):2547–2549. doi:10.2169/internalmedicine.8796-21
  • Takao D, Takeda K, Takazono T, et al. A case of drug-induced organizing pneumonia caused by amikacin liposome inhalation suspension. J Infect Chemother. 2023;29(8):806–808. doi:10.1016/j.jiac.2023.04.013
  • Matsumoto K, Nakao S, Hasegawa S, et al. Analysis of drug-induced interstitial lung disease using the Japanese adverse drug event report database. SAGE Open Med. 2020;8:1–13. doi:10.1177/2050312120918264
  • Cheng SL, Wang HC, Yang PC. Paradoxical response during anti-tuberculosis treatment in HIV-negative patients with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2007;11(12):1290–1295.
  • Im Y, Hwang NY, Kim K, Kim H, Kwon OJ, Jhun BW. Impact of time between diagnosis and treatment for nontuberculous mycobacterial pulmonary disease on culture conversion and all-cause mortality. Chest. 2022;161(5):1192–1200. doi:10.1016/j.chest.2021.10.048
  • Hasegawa N, Nishimura T, Ohtani S, et al. Therapeutic effects of various initial combinations of chemotherapy including clarithromycin against Mycobacterium avium complex pulmonary disease. Chest. 2009;136(6):1569–1575. doi:10.1378/chest.08-2567

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.